Fig. 4From: CRISPR based therapeutics: a new paradigm in cancer precision medicineWorkflow of optimized CRISPR-unique molecular identifier (UMI) pooled screen for identification of cancer patient-specific therapeutic targets. Ex vivo (patient derived organoid-based) or in vivo (patient derived xenograft-based) CRISPR screens are performed with barcoded guide RNA libraries for identification of individualized therapeutic targets with greater statistical power as these screens address the aspect of random clonal drift in the cell population that is being assayed. Created with BioRender.com with granted permission and licenseBack to article page